The patient presented with metastatic PDAC after a history of unrelated endometrial cancer; while there was no germline mutation to explain the tumour co-occurrence, ultimately, somatic profiling revealed a CTRC-NTRK1 gene fusion that was therapeutically actionable in the PDAC. This evidence concerns the gene NTRK1 and endometrial cancer.